AbbVie Sees Unusually Large Options Volume (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 86,296 call options on the company. This is an increase of 445% compared to the average daily volume of 15,836 call options.

AbbVie Price Performance

NYSE ABBV traded up $9.22 during trading on Wednesday, reaching $283.58. 5,585,527 shares of the company’s stock were exchanged, compared to its average volume of 6,410,414. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $285.40. The business has a 50 day moving average price of $260.41 and a 200-day moving average price of $237.87. The stock has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a PEG ratio of 1.28 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 EPS. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie will post 13.95 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays increased their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Piper Sandler upped their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. increased their price target on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Citigroup lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Finally, BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed that a subcutaneous version of SKYRIZI produced meaningful clinical and endoscopic responses in adults with moderately to severely active Crohn’s disease, with a safety profile consistent with the established treatment. The results could support regulatory review of a more convenient induction option and expand SKYRIZI’s commercial opportunity. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Additional SKYRIZI and RINVOQ inflammatory bowel disease updates, along with expectations for strong growth from Rinvoq, Skyrizi and Vraylar, have improved confidence in AbbVie’s post-Humira revenue drivers. RBC also expects the company to deliver a third-quarter top-line beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Erste Group Bank raised its FY2027 EPS forecast for AbbVie to $16.34 from $16.19 and maintained a Buy rating. Several analysts have also remained constructive, including RBC, which reaffirmed an Outperform rating. AbbVie analyst estimate update
• Neutral Sentiment: Analysts and investors remain divided on valuation. Comparisons with Sanofi favor Sanofi because of its upgraded outlook, Dupixent growth and lower valuation, while other analyses argue AbbVie’s recent pipeline wins could make the shares undervalued over the long term. Sanofi or AbbVie comparison
• Negative Sentiment: One recent valuation analysis placed AbbVie’s estimated fair value below the market price, highlighting downside risk if the company’s pipeline or earnings growth fails to meet elevated expectations.
• Neutral Sentiment: An executive sale of AbbVie shares may attract some investor attention, although the available reports do not indicate that it reflects a change in the company’s fundamental outlook.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Trading of AbbVie

Several large investors have recently made changes to their positions in ABBV. Corient Private Wealth LP bought a new position in AbbVie during the 2nd quarter worth $559,736,000. Legal & General Group Plc acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $2,905,952,000. Jupiter Topco LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $1,560,354,000. Diamant Asset Management Inc. increased its stake in shares of AbbVie by 21,649.0% in the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after acquiring an additional 3,654,351 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AbbVie in the 2nd quarter valued at $817,473,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.